New HPV cancer drug enters human testing
NCT ID NCT05976828
First seen Nov 01, 2025 · Last updated Apr 23, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called IBRX-042 in people with HPV-related cancers that have come back or gotten worse. The main goals are to find the safest dose and see what side effects occur. Twelve participants will receive three injections of the drug, one every three weeks, and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine (CSSIFM)
El Segundo, California, 90245, United States
-
Texas Oncology Austin Central
Austin, Texas, 78731, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.